Literature DB >> 989967

Alteration of plasma antithrombin III levels in ischemic heart disease.

R H Yue, M M Gertler, T Starr, R Koutrouby.   

Abstract

The amount of antithrombin III in plasma was determined quantitatively in 218 males between 45-60 years of age. The mean antithrombin III value was found to be low in the group with low risk for ischemic heart disease, intermediate in the group with high risk for ischemic heart disease and highest in the group with acute myocardial infarction. Concomitant study of kaolin-activated partial thromboplastin time revealed a sharp decrease in its mean value in the group with acute myocardial infarction. The high correlation between antithrombin III and kaolin-activated partial thromboplastin time for the entire population suggests that the development of ischemic heart disease is a gradual process and that failure of the damping mechanism results as an acute event. These findings may be useful in the determination of the coagulation state of these patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 989967

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Haemostatic function in myocardial infarction.

Authors:  A Hamsten; M Blombäck; B Wiman; J Svensson; A Szamosi; U de Faire; L Mettinger
Journal:  Br Heart J       Date:  1986-01

2.  Antithrombin III in patients on long-term oral anticoagulants.

Authors:  H Bull; I Mackie; M Brozović; D Woodings
Journal:  J Clin Pathol       Date:  1980-12       Impact factor: 3.411

3.  Relation between antithrombin III and clinical and serological parameters in systemic lupus erythematosus.

Authors:  M P Jarrett; D Green; C H Ts'ao
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

4.  Haemostatic variables associated with diabetes and its complications.

Authors:  J H Fuller; H Keen; R J Jarrett; T Omer; T W Meade; R Chakrabarti; W R North; Y Stirling
Journal:  Br Med J       Date:  1979-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.